Traws Pharma Q2 net loss widens to $3.0 million; no revenue, cash $5.0 million
Traws Pharma reported its quarter ended June 30, 2026, with no revenue, compared with $2.7 million a year earlier, and a net loss of $3.0 million, or $0.16 per share, versus a $0.9 million loss, or $0.11 per share, in the same period of 2025. The company said its cash and equivalents, plus expected at-the-market equity proceeds, should fund operations into the first quarter of 2027, and that it may need additional financing after that.
Key points
- Q2 2026 revenue was zero, down from $2.7 million in Q2 2025, which included a non-recurring deferred revenue recognition tied to a licensing termination.
- Q2 2026 net loss was $3.0 million ($0.16 per share); six-month net loss was $10.2 million, compared with $20.6 million net income in the first half of 2025, which included a $26.7 million non-cash warrant gain.
- Cash and cash equivalents were $5.0 million at June 30, 2026, up from $3.8 million at December 31, 2025, mainly from the April 2026 private placement and ATM sales.
- Shareholders approved the Series B and Series C financing tranches on July 8, 2026; the company says access remains subject to milestones and investor participation, and the FDA clinical hold on tivoxavir marboxil is still pending resolutio
The filing
Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 14, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.